In Issue 007, Sam walked the Lab through what happens when a drug finally reaches patients: not the trial, but the moment a treatment becomes standard of care. Rooty had the 30-year survival data. The numbers were striking.

Debby read the whole thing. She did not say much afterward. She had been quieter in the Lab lately. Not absent. Quieter. In Issue 008, Cora helped Debby understand why throwing data at their friend needing cancer treatment wasn't the wrong facts, but it needed heart to lead first before the data.

The message appeared on a Tuesday afternoon.

"Hi everyone. I have been following this Lab since Issue 004. I have sickle cell disease. I wanted to let you all know that I just got enrolled in a Phase II trial at my hospital. I thought maybe this was the right place to talk about it."

Her name was Vera Santiago. She had been reading for months, asking nothing, just watching the conversation.

Sam the Skeptic pinned the post.

Debby saw it come through.

Debby had a response ready. She had been in enough conversations about clinical trials to know the questions people usually asked. She could list the Phase I to III arc by memory now. She knew about randomization, about Data Safety Monitoring Boards, about blinded analysis. She had absorbed issues of this newsletter.

Debby started typing. Then she stopped.

On the edge of her desk was a small card. She had put it there after Issue 008. 4 lines on it.

She read the first line twice. Then she deleted what she had typed.

She wrote instead: "Vera, welcome. What made you decide to say yes?"

The OPEN Card, the PAUSE Protocol, and the Skeptic's Toolkit with examples in the roottorx.com/field-guide

Vera answered the same evening.

"My aunt had sickle cell. She enrolled in a trial 12 years ago. That trial helped generate data for a drug that is now a standard treatment option. She didn't benefit from it directly. She was too far into the disease by the time it was approved. But she said yes because she knew the evidence had to come from somewhere. Someone had to be the person who said yes first."

"I think about her a lot. I am trying to be the version of her for whoever comes after me."

Debby read it 3 times.

She typed: "That is one of the most honest things I have read in this Lab."

She meant it.

Throughout the previous Root Room issues, we navigated through various rooms looking at how misinformation spreads with Dr. Anecdote, how it gets amplified by Echo the Algorithm, how fear can drive people to reaffirm their self-beliefs. Now it is time to shift into some of the rooms that make or break a potentially life-changing therapeutic from getting to market. We will follow Vera through her clinical research journey as a typical experience for anyone who might consider a clinical trial.

The trial site was on the 4th floor of Vera's hospital. She had been to that building dozens of times. She had never been to that floor.

The Primary Investigator, Dr. Kiko, and the coordinator, Nurse Nani, were waiting for her. Nani had a leather binder that looked like it had seen several careers. She set it on the table between them and did not open it right away.

"The consent form is 27 pages," Nani said. "Before we go through it, I want to ask you something. What do you already know about what you might be agreeing to?"

Vera had done her reading. She knew about randomization. She knew she might receive the investigational compound or the current standard of care. She knew the trial was being monitored by an independent board.

She had one question. She had read about it in the Facebook Root to Rx Lab group.

"Can you tell me about the data monitoring committee? What triggers a review?"

Nani looked up from her binder.

"You have done your reading."

"I had help," Vera said.

They went through the consent form together, page by page. Nani did not read it to her. Dr. Kiko and Nani asked Vera to walk through each section in her own words and tell them what she understood it to mean. When Vera's understanding was incomplete, Nani or Dr. Kiko filled in the gap. When it was correct, Nani confirmed it and moved on.

It took a long time. Nani did not rush.

Vera signed at the bottom of page 27. Dr. Kiko witnessed it, wrote the time, and Nani closed her binder.

Consent form, DSMB, randomization, blinding, screening period, terms from Vera's consent day, defined in plain language. New to trial terminology? The Field Guide glossary covers it. roottorx.com/field-guide

Signing the Informed Consent is the first step of a clinical trial. With that signed, the research site can obtain medical records to assess eligibility criteria. This also starts a screening period. Usually 2 to 4 weeks of lab work, scans, and study-specific procedures to ensure the patient meets inclusion criteria, and does not meet any exclusionary criteria. Patient enrollment is often similar to the porridge in Goldilocks. Too sick, and the patient may progress too quickly and the medicine cannot work fast enough. Not sick enough, there will not be a meaningful improvement.

After 3 weeks of lab draws, MRI scans, and questionnaires, she got the confirmation that she met the eligibility criteria and needed to schedule the enrollment visit, which often is a day of baseline testing just prior to dosing, then dosing.

After confirming Vera's eligibility in the study's Interactive Response Technology (IRT), the software that randomizes which study arm the patient will be assigned to, Nani printed the confirmation of which bottle to pull Vera's medication from. For some studies, the site does not know what treatment. Others, open-label studies where it's very clearly a drug infusion while the other option is a new oral tablet, it's clear which arm the patient is in. For this one, Nani, Dr. Kiko, and the whole study were blind until the end of the study.

Baseline labs and ECG tracings were done, and Nurse Nani looked at Vera while handing her the pill with a glass of water. "You know, you're taking a step that thousands and thousands of people before you have taken. And we're one step closer to advancing this area of treatment because you are volunteering," she said, with the warmest smile on her face. Nurse Nani wanted to go on and on about the clinical trials she's seen close early because they couldn't find enough patients, and all the possible treatments that came to premature demises. But she knew there was a lot to get through for the visit still.

Vera posted to the Root to Rx Lab Facebook group from the waiting room afterward.

"First dose done. Nothing dramatic. I feel exactly like I did this morning."

A pause, then a second message: "Unremarkable. Which I think is the point."

Rooty shared the IRIS trial enrollment data in response. 1,106 patients across 16 countries. The trial that built the case for Gleevec. Filled in 18 months. Partly because patients found each other on message boards in 1999 and told each other it was worth doing.

Sam added one line: "Vera just did that for whoever comes next."

He would save it for Issue 011, where it belonged. But Debby had already looked it up.

85% of people eligible for a clinical trial never enroll. Not because the drug isn't worth it. More often it's because no one told them, they didn't know clinical trials existed, no one thinks to search online for a clinical trial. Because the site was too far. Because they read that trials are only for people with nothing left to try, and they still had something left to try. Because people don't want to be a guinea pig.

Vera had something left to try. She said yes anyway.

Debby closed her laptop and did not open social media for the rest of the evening. She was thinking about the card on her desk and how many times she had been the wrong kind of helpful.

The FDA gets the Gleevec file. A 2.5-month review clock starts. Debby asks a question in the Lab that nobody expects. And Nani says something about the approval process that she has never said to a group before.

The views expressed on Root to Rx are my own and do not represent the views or positions of my employer, or any affiliated organization.

Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States